Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed Primary Central Nervous System Lymphoma-A Randomized Controlled Trial

NCT07185373 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT07185373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07185373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed Primary Central Nervous System Lymphoma-A Randomized Controlled Trial
Lead sponsor
Huashan Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 1, 2025
Completion date
July 30, 2029
Enrollment
215 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma